Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer（NSCLC）
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorQian Chu
About this trial
This observational study aims to construct and validate the performance of a multimodal predictive model in forecasting the outcomes of neoadjuvant therapy in patients with NSCLC.
The core research question is: Can a multi-model approach predict outcomes of neoadjuvant therapy for non-small cell lung cancer and provide clinical recommendations?
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
pathologically diagnosed non-small cell lung cancer
The treatment plan is：receiving neoadjuvant chemo-immunotherapy during the study period, followed by surgical resection
Disqualifiers
recurrent or metastatic lung cancer;
patients with other primary tumors
Trial population
NSCLC patients suitable for neoadjuvant therapy
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
500 Participants
are grouped into 2 trial groupsGroup A: NSCLC with neoadjuvant therapy but without surgery
Group B: NSCLC with neoadjuvant therapy and surgery
Trial outcomes
Primary outcomes
1
pathologic response
Time frame
PerioperativeSecondary outcomes
1
EFS
event free survival
Time frame
One year after the treatment endedSponsors and contacts
Click on the lead sponsor to view all of their trials.
Qian Chu
Lead sponsor
Tongji Hospital
Sponsor institution
Source ClinicalTrials.gov